Intangibles.

[Deleted]

Could there be something that management is not telling investors? Possibly, not able to tell us. For example, Haken is still getting paid. Could the Mann family trust have a big role in decision making: how to price Afrezza, who we can and can not partner with, how much the company can be sold for etc. Im sure there are foreign companies who would be willing to roll the dice for rights to Frezza, why not? UK rights and percentage of sales for ＄30-50 million, for example. This would extend the runaway and give us another revenue stream. How much can the right of first refusal be valued with Amphiptar(sp)?

[matt]

Shareholders have a legal right to know any material information about the company. If the Mann trusts had decision making power of any type that would have been a required disclosure long ago. Whatever else you think about management, their SEC filings are in order.

As for foreign companies willing to roll the dice, don't be so sure. Why should anybody pay $30-50 million for UK rights when, two years after launch, the cumulative retail sales in the US market have barely reached $20 million and prices in the UK are an order of magnitude lower? That one just doesn't pass the reality check. It seems like a good idea at first glance, but fixing a US marketing problem by going international rarely works for any company.

[sayhey24]

Feb 4, 2017 8:17:12 GMT -5 @georgethenite said:

Could there be something that management is not telling investors? Possibly, not able to tell us. For example, Haken is still getting paid. Could the Mann family trust have a big role in decision making: how to price Afrezza, who we can and can not partner with, how much the company can be sold for etc. Im sure there are foreign companies who would be willing to roll the dice for rights to Frezza, why not? UK rights and percentage of sales for ＄30-50 million, for example. This would extend the runaway and give us another revenue stream. How much can the right of first refusal be valued with Amphiptar(sp)?

There better be a lot management is not telling us because if they have told us everything Mannkind is doomed.  If they think a bunch of Fuller Brush sales guys going door to door are going to make the market for afrezza, its not going to happen.  They better be talking with Ondou, Dexcom, Medtronic, IBM, Teva, Abbott, Beyer and San Meditech to name a few.  Only technology is going to sell afrezza because until people see the CGM real time results not many can understood what Al Mann understood.

[lennymnkd]

Great post seyhey! / tech will sell AFREZZA ... the whole ball of wax/

[Deleted]

Feb 4, 2017 10:03:11 GMT -5 sayhey24 said:

Feb 4, 2017 8:17:12 GMT -5 @georgethenite said:

Could there be something that management is not telling investors? Possibly, not able to tell us. For example, Haken is still getting paid. Could the Mann family trust have a big role in decision making: how to price Afrezza, who we can and can not partner with, how much the company can be sold for etc. Im sure there are foreign companies who would be willing to roll the dice for rights to Frezza, why not? UK rights and percentage of sales for ＄30-50 million, for example. This would extend the runaway and give us another revenue stream. How much can the right of first refusal be valued with Amphiptar(sp)?

There better be a lot management is not telling us because if they have told us everything Mannkind is doomed.  If they think a bunch of Fuller Brush sales guys going door to door are going to make the market for afrezza, its not going to happen.  They better be talking with Ondou, Dexcom, Medtronic, IBM, Teva, Abbott, Beyer and San Meditech to name a few.  Only technology is going to sell afrezza because until people see the CGM real time results not many can understood what Al Mann understood.

And this is what makes Afrezza a niche drug. 

[lennymnkd]

Niche drug ! Quite the opposite........this technology pareing makes  the market greater than any other  product in the total diabetes space . For prandial insulin .

[sayhey24]

Feb 4, 2017 14:51:49 GMT -5 @reverselo said:

Feb 4, 2017 10:03:11 GMT -5 sayhey24 said:

There better be a lot management is not telling us because if they have told us everything Mannkind is doomed.  If they think a bunch of Fuller Brush sales guys going door to door are going to make the market for afrezza, its not going to happen.  They better be talking with Ondou, Dexcom, Medtronic, IBM, Teva, Abbott, Beyer and San Meditech to name a few.  Only technology is going to sell afrezza because until people see the CGM real time results not many can understood what Al Mann understood.

And this is what makes Afrezza a niche drug. 

I don't know about that it seems every endo is now selling the Libre since its a money maker for them.  It does everything the T2 needs and aside from alarms is good enough for the T1 at $70 a sensor which is fully covered by Medicare.  For $100 the PWD can get their own "non-approved" reader and download the results to their PC and the "cloud" to go into the Endo's FreeStyle View system.  Dexcom and Onduo and the rest better get moving as Abbott has the best dollar for dollar offering and its available now.  Its a better buy than getting a $20 meter and then the strip cost.

[dreamboatcruise]

Feb 4, 2017 10:03:11 GMT -5 sayhey24 said:

Feb 4, 2017 8:17:12 GMT -5 @georgethenite said:

Could there be something that management is not telling investors? Possibly, not able to tell us. For example, Haken is still getting paid. Could the Mann family trust have a big role in decision making: how to price Afrezza, who we can and can not partner with, how much the company can be sold for etc. Im sure there are foreign companies who would be willing to roll the dice for rights to Frezza, why not? UK rights and percentage of sales for ＄30-50 million, for example. This would extend the runaway and give us another revenue stream. How much can the right of first refusal be valued with Amphiptar(sp)?

There better be a lot management is not telling us because if they have told us everything Mannkind is doomed.  If they think a bunch of Fuller Brush sales guys going door to door are going to make the market for afrezza, its not going to happen.  They better be talking with Ondou, Dexcom, Medtronic, IBM, Teva, Abbott, Beyer and San Meditech to name a few.  Only technology is going to sell afrezza because until people see the CGM real time results not many can understood what Al Mann understood.

Any medical technology takes a long time to make it through the FDA process.  Dexcom has only very recently been approved to have CGM used for purposes of determining insulin dosing... though granted some patients have been using them for that unapproved purpose for a long time.  No amount of talking with IBM or others is going to generate some game changing technology that could be in clinical use in time to assist Afrezza launch.  Other than Dexcom, that is.  Maybe there would be some partnership opportunity there, but the counter argument is that until Afrezza has some meaningful user base and better payer coverage, Dexcom is likely to want to stay agnostic to prandial insulin.  Dexcom and MNKD both have relatively poor payer coverage.  If they were promoting CGM+Afrezza solution, the number of people that would have easy payer coverage for both would be the union of good coverage, which would likely be quite small.

So if Mannkind and Dexcom were to be working on something, it likely would not be consumer promotion at this point but rather jointly trying to convince payers to buy into "real time" insulin.  Management did mention that new clinical trials would aim to show better "time in range".  Will be interesting to see whether that trial will be based on the newly approved ability to base dosing dynamically on Dexcom CGM readings or whether it might use the newly approved Freestyle which doesn't give users feedback... or perhaps  have two arms to prove better time in range for "with CGM" and "without CGM".

@georgethenite... I think we can be pretty certain that there is no company willing to spend $30+ million for UK rights... I'm confident MNKD would jump on that at this point if it were being offered.  We wouldn't need to be doing risky RS if a pharma company were willing to spend that kind of money on rights for UK.  That would be a no brainer for MNKD given the financial difficulties currently being faced.

[dreamboatcruise]

Feb 4, 2017 15:42:39 GMT -5 sayhey24 said:

Feb 4, 2017 14:51:49 GMT -5 @reverselo said:

And this is what makes Afrezza a niche drug. 

I don't know about that it seems every endo is now selling the Libre since its a money maker for them.  It does everything the T2 needs and aside from alarms is good enough for the T1 at $70 a sensor which is fully covered by Medicare.  For $100 the PWD can get their own "non-approved" reader and download the results to their PC and the "cloud" to go into the Endo's FreeStyle View system.  Dexcom and Onduo and the rest better get moving as Abbott has the best dollar for dollar offering and its available now.  Its a better buy than getting a $20 meter and then the strip cost.

What is the managed care payer coverage like for the sensors?  Unfortunately, Afrezza still has very poor Medicare coverage.

If what you say about pricing is true it may be cheaper for insurers to pay for the sensors than strips... but it would seem they wouldn't do that at this point because the Libre isn't approved in US to provide patients with readings... even if "non-approved" readers can be obtained by the patients.  Would payers consider the cost/benefit equation of Libre based on "off-label" use?  

[Deleted]

Feb 4, 2017 9:20:26 GMT -5 matt said:

Shareholders have a legal right to know any material information about the company. If the Mann trusts had decision making power of any type that would have been a required disclosure long ago. Whatever else you think about management, their SEC filings are in order.

As for foreign companies willing to roll the dice, don't be so sure. Why should anybody pay $30-50 million for UK rights when, two years after launch, the cumulative retail sales in the US market have barely reached $20 million and prices in the UK are an order of magnitude lower? That one just doesn't pass the reality check. It seems like a good idea at first glance, but fixing a US marketing problem by going international rarely works for any company.

While I respect your opinion, I would say that countries other than the US happily have socialized medicine. Where most everyone pays the same fixed cost. We dont negotiate with health companies, rather governments.

I am in Japan. Did you know that 1 in 5 Japanese are now considered diabetic. This is according to a news report done by NHK yestesday.

This brings me to my next point: the hatred of using needles. I can say unequivocally that people here HATE needles!

Offer AFFREZZA at the lowest possible point where a profit can be made, and let thd users decide. We will exist in the future! We just need exposure outside the US!